Biomea Fusion (BMEA) Long-Term Investments (2021 - 2022)
Biomea Fusion (BMEA) posted Long-Term Investments of $10000.0 for Q3 2022, down 94.62% sequentially from $186000.0 in Q2 2022, and down 99.55% YoY from $2.2 million in Q3 2021.
Biomea Fusion (BMEA) Long-Term Investments (2021 - 2022) Analysis & Trends
Biomea Fusion has reported Long-Term Investments for 2 years, with the latest figure at $10000.0 in Q3 2022.
- Quarterly Long-Term Investments fell 99.55% year-over-year to $10000.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $10000.0 (down 99.55% YoY) and the FY2021 annual result came in at $1.9 million, changed N/A from the prior year.
- Long-Term Investments fell to $10000.0 in Q3 2022 per BMEA's latest filing, from $186000.0 in the prior quarter.
- Over five years, Long-Term Investments peaked at $11.8 million in Q1 2021 and troughed at $10000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 10,000.00 |
| Jun 30, 2022 | 186,000.00 |
| Mar 31, 2022 | 415,000.00 |
| Dec 31, 2021 | 1.88 Mn |
| Sep 30, 2021 | 2.24 Mn |
| Jun 30, 2021 | 4.26 Mn |
| Mar 31, 2021 | 11.84 Mn |